Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Cerebrolysin TBI: Comparison Across Neuroprotective Agents

The table below compares Cerebrolysin against other compounds investigated for TBI neuroprotection, evaluating mechanism, clinical trial status, and practical constraints. Cerebrolysin Neurotrophic peptide mixture activating Trk receptors; promotes neuronal su

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • The table below compares Cerebrolysin against other compounds investigated for TBI neuroprotection, evaluating mechanism, clinical trial status, and practical constraints.
  • Cerebrolysin
  • Neurotrophic peptide mixture activating Trk receptors; promotes neuronal survival and synaptic plasticity
  • Phase III completed; multiple RCTs show cognitive benefit
  • Effect size diminishes after 24-hour delay; not FDA-approved
  • Intravenous infusion (30–50ml daily × 10–21 days)
  • Strongest evidence for moderate TBI cognitive outcomes; narrow therapeutic window demands early initiation
  • Progesterone
  • Neurosteroid with anti-inflammatory and anti-apoptotic effects via genomic and non-genomic pathways
  • Phase III trials (SYNAPSE, PROTECT III). Both failed to show benefit
  • Large Phase III trials showed no mortality or functional benefit despite promising Phase II data
  • Intravenous infusion or intramuscular injection
  • Early promise not replicated in adequately powered trials; unlikely to advance to FDA approval
  • Cyclosporine A
  • Inhibits mitochondrial permeability transition pore; reduces excitotoxic cell death
  • Phase II completed; Phase III not initiated
  • Narrow therapeutic index; significant immunosuppression risk limits utility in trauma populations
  • Intravenous infusion
  • Mechanism is sound but safety profile prohibits widespread use in acute TBI
  • N-acetylcysteine (NAC)
  • Antioxidant and glutathione precursor; reduces oxidative stress markers
  • Phase II completed with mixed results
  • Effect sizes modest; primarily studied in mild TBI/concussion rather than severe injury
  • Oral or intravenous
  • May have role in mild TBI but insufficient evidence for moderate-to-severe cases
  • Erythropoietin (EPO)
  • Anti-apoptotic and anti-inflammatory via EPO receptor activation on neurons and glia
  • Multiple Phase II trials; results inconsistent
  • Increased thrombotic risk at neuroprotective doses; inconsistent trial outcomes
  • Intravenous or subcutaneous injection
  • Risk-benefit ratio unfavorable compared to Cerebrolysin; hematologic side effects limit application

Related resources

More comparisons